IBT - International Brachytherapie - 500 Beiträge pro Seite

[meinolf67]

... ist seit kurzem Eckert&Ziegler Tochter und sollte deshalb im Auge behalten werden.


Leider ist die Webseite im moment offline...

[meinolf67]

06.02.2006 14:38
Implant Sciences and International Brachytherapy Form Business Alliance for Prostate Seed Distribution
Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced that the Company and International Brachytherapy s.a. (Euronext: "IBTB") have entered into an agreement whereby Implant will expand its prostate seed offering to include International Brachytherapy's ("IBt") polymer encapsulated palladium 103 seed. Belgium-based IBt is one of only two radioactive prostate seed manufacturers in the world who own cyclotrons and are able to synthesize their own Palladium-103 isotope. In addition, IBt's polymer encapsulation is believed to have numerous competitive advantages, including a simple, less expensive method of stringing seeds together to form "strands," a popular value added packaging configuration.

The agreement provides for Implant to be a distributor of IBt's Palladium-103 radioactive prostate seeds in the U.S. As a result, Implant's ability to sell into the radioactive prostate seed market should be enhanced by making available both the IBt Palladium-103 radioactive prostate seed in addition to the Company's currently available Iodine-125 radioactive prostate seed.

Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, (News) commented, "We are pleased to announce this important alliance between IBt and Implant for the distribution of Palladium radioactive prostate. By supplementing our current Iodine-125 prostate seed offering with IBt's Palladium-103 seed, Implant can now compete more effectively by offering physicians a choice of either of the two (2) established radioactive seed types currently used for the treatment of prostate cancer."

About Implant Sciences

Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives which are distributed under the Quantum Sniffer(TM) brand name. The Company also provides state of the art ion implantation and wafer analytical services for the semiconductor industry. The Company also develops, manufactures and sells radioactive products for the treatment of cancer, including sales of radioactive seeds for the treatment of prostate cancer and development of a new, FDA approved radioactive source for use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com.

About International Brachytherapy s.a. (News)

International Brachytherapy s.a. ("IBt"), a Belgian company listed on Euronext, designs, produces and sells worldwide a complete range of radiotherapy implants used in brachytherapy. Brachytherapy is a medical technology by which implants containing radioisotopes are placed in the heart of cancer tissue. The local radiation from the implants then destroys the cancerous cells. The main application for Brachytherapy today is for treating localized prostate cancer. For further details on IBt and its products please visit IBt's website at www.ibt4seeds.com.

Implant Sciences believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the period ended June 30, 2005, and Quarterly Report on Form 10-Q for the period ended September 30, 2005. The Company assumes no obligation to update the information contained in this press release.

[meinolf67]

Bt - International Brachytherapy s.a. : Annual results 2007
(06/03/08 17:40 CET)


Annual results 2007
EMBARGO until
Thursday 6 March 2008 - 17.40 Brussels time

2007 Results
- Impact of the decision to stop direct sales activities in USA
- Q4 2007 results demonstrate clear Progress

Prospects
- No. 1 in Europe with acquisition of Bebig GmbH
- Net profit expected in 2008

KEY CONSOLIDATED FIGURES - IFRS

+------------------------------------------------------------+--------+--------+----------+--------+

| (in thousands of EUR) |FY 2007 |FY 2006 |Var. in % |Q4 2007 |

+------------------------------------------------------------+--------+--------+----------+--------+

|Sales and services | 10.945 | 9.595 | + 14% | 3.156 |

+------------------------------------------------------------+--------+--------+----------+--------+

|a. Turnover | 8.840 | 8.329 | + 6 % | 2.181 |

+------------------------------------------------------------+--------+--------+----------+--------+

|b. Other income | 2.105 | 1.266 | + 66 % | 975 |

+------------------------------------------------------------+--------+--------+----------+--------+

|EBITDA (1) | (705) | 131 | n/a | (13) |

+------------------------------------------------------------+--------+--------+----------+--------+

|Operating result |(2.280) | (1323) | -72 % | (225) |

+------------------------------------------------------------+--------+--------+----------+--------+

|Net financial result | 261 | 47 | + 115 % | 339 |

+------------------------------------------------------------+--------+--------+----------+--------+

|Current result |(2.019) |(1.276) | - 58 % | 113 |

+------------------------------------------------------------+--------+--------+----------+--------+

|Net result - IBt share |(2.369) |(1.444) | - 64 % | 61 |

+------------------------------------------------------------+--------+--------+----------+--------+

|Impact of discontinued activities |(6.244) | n/a | n/a | n/a |

+------------------------------------------------------------+--------+--------+----------+--------+

|Net result - IBt share, after discontinuation of activities |(8.613) | n/a | n/a | n/a |

+------------------------------------------------------------+--------+--------+----------+--------+



The figures in this table, expressed in thousands of EUR, are the consolidated results of the IBt group.

(1) EBITDA = Earnings Before Interest, Taxes, Depreciation and Amortization
(2) The presentation of the data for 2006 has been slightly modified (from that given in the press release of 28 February 2007) to bring it in line with current IFRS nomenclature. This change in presentation does not affect turnover, net result or EBITDA.
(3) The statutory auditor has confirmed that, at the present stage of his ongoing audit, there are no elements that could alter significantly the financial information contained in this press release.

KEY ITEMS

Turnover generated by sales of products after margin rebates to distribution partners is up 6% compared to last year. These sales consisted essentially (over 80%) of sales of Iodine-125 implants on the European continent. The balance was made up of sales by the US subsidiary, IBt Inc., for the first three quarters of the year (in an amount of EUR 0.83 million), and initial sales of brachytherapy equipment and accessories by IBt as a distributor for the products of Isodose Control and IBA.

Other operating income relates mainly to capitalized production, to amounts received from IsoRay under the technology licence signed between the two companies at the start of the year, and to a major relinquishment of a receivable (non-recurrent by nature). Operating charges break down into purchases of raw materials (EUR 2.85 million), services and other goods (EUR 3.81 million), wages and salaries (EUR 4.89 million), depreciation and amortization (EUR 1.58 million) and other costs (EUR 0.1 million).

The financial result represents essentially the income from short-term treasury investments.

EBITDA and current result are down. These were affected this year by two main sources of loss: (1) the operating results of the US subsidiary IBt Inc., and (2) the production of the Pd-103 radioactive isotope at the Seneffe site and the assembly activity of the related implant.

Net result is affected by a non-recurrent loss of EUR 6.24 million. This loss is slightly higher than initially estimated, owing a currency loss recorded on the receivable held on the american subsidiary.
This non-recurrent book loss was already announced and recorded in the third quarter results. Essentially it did not have any cash impact. The main elements of this loss are:
- Accelerated depreciation and amortization of tangible and intangible assets (EUR 5.4 million). These relate mainly to (1) the two cyclotrons installed on the Seneffe site, and (2) the capitalized costs of developing the OptiSeed103 implant.
- Write-downs (EUR 0.2 million) on the inventory of raw materials and finished products.
- Personnel costs and other expenses (EUR 0.4 million), consisting of severance indemnities, contractual indemnities and provisions.
- Currency translation loss on receivables (EUR 0.3 million).

COMMENTS

The group results reflect a difficult year for IBt.

They have been severely affected by the loss related to the decision to stop direct sales activities in the United States and the corollary decision to cease production of the Pd-103 isotope and the associated product at the Seneffe site.

The reasons for these decisions lie in recent changes in the US health care reimbursement system and the unfavourable evolution of the EUR-USD exchange rate. These decisions had the effect of cutting the two major sources of losses, which were also generating a major cash drain for the group. It was anticipated that these decisions would negatively impact turnover but positively affect the net result (cf. press release of 27 November 2007).

Indeed, results from the last quarter of 2007 onwards are encouraging. Sales in the fourth quarter were up 9% on the third quarter despite the absence of income from the US market, with the EBITDA result practically in balance.

OUTLOOK

Looking forward, the recent acquisition of the activities of the Bebig GmbH group in the field of permanent implants considerably modifies the group's prospects.

With this acquisition, that was finalized last week, IBt has doubled in size. The group now has a market share of over 40% and is taking a clear leadership position in its field of activity at the European level. Today it is active on practically every major European market through its subsidiaries in France, Netherlands, Germany, United Kingdom, Belgium, Italy and Spain and an extensive network of distributors.

In 2008 more than 5,000 men will be treated with the group's products.

The first priority today is to rapidly integrate the distribution networks, the operating groups at Berlin and Seneffe, and the teams of the two companies.

In the coming quarters, IBt will continue its development strategy aimed at creating a group with a strong identity, seen as the reference in the field of brachytherapy cancer treatment and innovation in this specific segment.

This strategy will be based both on organic growth (through expanding its distribution network and extending its product portfolio) and on external growth. In this context, and as part of the deal with the Eckert Ziegler group, IBt holds an option to acquire another division of the group, which operates in the sector of cancer treatment with temporary implants ("afterloaders"), an area that is ideally complementary with IBt's activities. The option is valid for a year, but the company expects to take a rapid decision on this opportunity.

Diary

15 March 2008 - Participation in the "Shareholder's Day" organized by "Cash"
2 June 2008 - General Meeting of Shareholders

Contacts: [phone]
François Blondel, CEO
Laurence Goemaere, Investors Relations Manager
Internet: www.ibt.be

[meinolf67]

Antwort auf Beitrag Nr.: 34.142.326 von meinolf67 am 21.05.08 14:04:41

hatte falsche URL, richtig ist: www.ibt.be

[meinolf67]

IBt - International Brachytherapy s.a. : IBt results Q1 2008

IBt results Q1 2008

EMBARGO till Thursday May, 29 2008 17.40 Brussels time

- Revenues up + 15 % - First results following integration of BEBIG - Prospects for the year confirmed

CONSOLIDATED KEY FIGURES

(in thousands of EUR)

Q1 2008

Q1 2007

Var. in %
Sales and services 3,490 3,023 15%
a. Turnover 2,481 2,157 15%
b. Other income 1,009 866 16%
EBITDA1 671 590 14%
Operating result 383 181 112%
Net financial result -91 33 N/A
Current result 173 214 -19%
Net result � IBt share 107 112 -5%
Produced with reference to IFRS standards, the figures in this table, expressed in thousands of EUR, are consolidated but not audited. [1] EBITDA = Earnings Before Interest, Taxes, Depreciation and Amortization

Preliminary comment

The results for the first quarter of 2007 given in the table above reproduce the results as they were published in May 2007.

It should be pointed out that the comparability of the Q1 2008 and Q1 2007 figures is limited by the fact that the group's scope of activity has changed considerably between these two periods. More exactly:

(1) on the one hand the scope of the Group's activities was reduced by the relinquishment of the direct sale activities in the USA, which was decided in September 2007, along with the closing of the US subsidiary and the cessation of certain production activities in Belgium (Pd-103 implants),

(2) on the other hand, and in the other direction, this scope has been widened by the consolidation of the activities of BEBIG GmbH since 29 February 2008, following the acquisition of the shares of this company at the end of February 2008.

Income statement

Turnover, representing sales income after margin rebates to distribution partners, rose by 15 % compared with the same period in 2007. These sales consisted essentially of sales of iodine-125 implants on the European continent. Other operating income relates to the forgiveness of a major debt, an item that is by nature non-recurrent and non-cash, and capitalized production.

Operating charges break down into manufacturing costs (EUR 1.58 million), sales and marketing expenses (EUR 0.86 million), general and administrative expenses (EUR 0.47 million), research and development expenses (EUR 0.32 million) and other charges (EUR 0.02 million).

COMMENTS AND PROSPECTS

The acquisition of BEBIG GmbH at the end of February has considerably changed the group's prospects. By combining the two entities, the group has taken a clear leadership position in its field of activities in Europe.

Today it is active on practically all major markets through its subsidiaries in France, the Netherlands, Germany, the UK, Belgium, Italy and Spain, plus a wide distributor network.

By way of information, pro forma results are presented in the table below. These are the results that the group would have posted if the activities of the BEBIG group had been consolidated since 1 January 2008.

(in thousands of EUR)

Q1 2008

Q1 2007

Var. in %
Pro forma
Sales and services 5,451 3,023 80%
a. Turnover 4,373 2,157 103%
b. Other income 1,078 866 24%
EBITDA (1) 780 590 32%
Net result � IBt share 491 112 338%

In the coming quarters, IBt's primary objective will be to continue with its integration plan along with restructuring its activities. Its ambition is to create a group having a strong identity, which constitutes a reference for brachytherapy cancer treatment and for innovation in this specific segment.

With regard to IBt's option to acquire the division of the Eckert Ziegler group which operates in the sector of treating cancer with temporary implants ( afterloader ), discussions between the two groups are currently under way.

Finally, IBt confirms expecting to post its first annual profit in 2008, excluding potential restructuring charges.

[meinolf67]

2 June 2008 - IBt - (Reuters: IBTH.BR - Bloomberg: IBTB BB)

After informing workers' representatives, IBt presented to its General Meeting of shareholders, today, 2 June 2008, its intention to implement a plan to integrate and reorganize its activities.

Readers are reminded that, in February this year, IBt acquired control of BEBIG GmbH, a Germany company operating in the same sector as IBt, that is the treatment of certain forms of cancer with permanent implants. Today the group has two operating sites, at Seneffe and Berlin, both having largely the same activities.

This integration and reorganisation plan, if implemented, is intended to improve production efficiency at IBt and to achieve a better distribution of activities between the different group sites.

The broad lines of this integration plan involve (1) concentrating at Seneffe the Sales and Marketing activities, plus R&D relating to the intellectual property held by IBt , and all the general parent company departments (Finance, HR, IR, legal, etc.) and (2), concentrating the implants production activities on the Berlin site.

Out of a concern to respect all legislation in this matter, the company has therefore announced today its intention of closing the "Manufacturing" department of its Seneffe site and to proceed with a collective dismissal of workers. In accordance with the applicable procedures, senior management has proposed to the trade union organizations to initiate the information and consultation phase with a view to determining, on the one hand, the possibilities open in order to avoid or reduce the mass redundancies and, on the other hand, the social measures to be taken to attenuate the consequences of a collective dismissal.

[meinolf67]

Kurs 3,30

[meinolf67]

Antwort auf Beitrag Nr.: 34.441.941 von meinolf67 am 04.07.08 19:40:23

3,31

[meinolf67]

IBt - BEBIG wins tender for implants in Spain

IBt - (Reuters: IBTH.BR - Bloomberg: IBTB BB)

Seneffe, Belgium, September 3, 2008.

IBt, the European group specialized in providing seeds used in permanent brachytherapy implants for the treatment of cancer, announces that it has won a large tender to supply IsoCord® to the renowned Madrid cancer research center Hospital Universitario Ramón y Cajal.

This three year contract, for product valued in excess of 0.7 million euros, will further strengthen the position of the company on the Spanish market as a supplier of radiotherapy products. The contract is the fifth long-term supply contract for implants signed with a Spanish hospital since IBt incorporated its Spanish subsidiary earlier this year.

IsoCord® consists of a selectable number of linked seeds used primarily in the treatment of prostate cancer. The IsoCord® system with its convenient and well shielded strand cassette and dispensing device make for quicker procedures and reduced radiation exposure to personnel in the operating room. Long terms study have shown that permanent brachytherapy seed implants provide disease control at least as good as classical radical prostatectomy and external beam radiotherapy but with fewer side effects for patients. Prostate cancer is the commonest form of cancer in men, with about 135,000 new cases diagnosed in Europe every year.

IBt BEBIG Group designs, produces and markets worldwide a complete range of radiotherapy implants used in permanent brachytherapy. The group today includes subsidiaries based in Germany, France, UK, Ireland, Spain, and Italy as well as a large number of distributors spread throughout the world.

Contacts François Blondel, CEO

Laurence Goemaere, Investors Relations Manager

Tel: [phone]

E-mail: [e-mail]

Website: www.ibt.be

[meinolf67]

albjahreszahlen hatte es auch gegeben:

IBt - International Brachytherapy s.a. : Results IBt , H1, 2008

Results IBt , H1, 2008

Regulated Information

EMBARGO till 29 August 2008

17:40 Brussels time Major increase in operating results due to the integration of BEBIG GmbH Sales + 61 % EBITDA + 99% First time half-year profit (before restructuring charges) Seneffe restructuring completed Outlook confirmed

Financial results in summary

Preliminary comment

The figures in the following tables present the group's financial results with reference to IFRS standards. They are consolidated but not audited. It should be pointed out that the comparability of the H1 2007 and H1 2008 figures is limited due to the fact that the group's scope of activity has changed considerably between these two periods:

(1) Following the September 2007 decision to terminate activities connected with the isotope Pd-103, the financial data relating to H1 2007 as stated in the tables below has been adjusted to reflect the data relating solely to continuing activities, i.e. the production and sale of iodine-125 implants;

(2) on the other hand, the scope has been widened by the consolidation of the activities of BEBIG GmbH since 29 February 2008, following the acquisition of the shares of that company at that time.

Consolidated income statement

In EUR thousands

1st Half 2008

1st Half 2007

Variation
Turnover 6,881 4,264 + 61 %
Cost of sales -3,705 -2,131 + 74 %
Gross margin 3,175 2,133 + 49 %
Commercial and marketing expenses -2,018 -1,569 + 29 %
G&A expenses -1,209 -758 + 59 %
R&D expenses -353 -241 + 46 %
Other operating income and charges 1,401 735 + 73 %
EBITDA 1,646 826 + 99 %
EBIT 942 299 + 215 %
Financial result -145 62 NA
Result before taxes 796 361 + 120 %
Taxes -326 -84 + 288 %
Minority interests -97 -147 - 34 %
Net result – IBt share, before non-recurrent items 373 130 + 187 %
Discontinued activities -1,044 NA
Impact of restructuring -3,740 NA
Net result -3,366 -914 - 268 %

Balance sheet

In EUR thousands

On 30 June 2008

On 31 December 2007
Non-current assets 37,299 12,673
Intangible assets 864 6
Tangible assets 8,430 5,013
Financial assets 3,035 -
Deferred tax assets 7,653 7,653
Goodwill 16,784 -
Other non-current assets 534 1

Current assets 11,410 5,000
Inventories 2,035 798
Trade receivables 3,919 1,127
Other receivables 2,465 69
Cash and cash equivalents 2,990 3,006

Assets held for sale 137

TOTAL ASSETS 48,708 17,810

Equity 30,371 11,273
Minority interests 320 222
Provisions 4,652 62
Amounts payable after one year 6,352 3,103
Amounts payable within one year 7,014 2,831

Liabilities held for sale 320

TOTAL LIABILITIES 48,708 17,810

Evolution of shareholders' equity



Capital

Issue premium

Reserves

Translation differences

Equity
Carrying value on 31/12/2007 6,692 30,946 -26,256 -110 11,272
Result of the period -3,366 -3,366
Translation differences -159 -159
Capital increase 4,183 19,239 23,422
Other variations -798 -798
Carrying value on 30/06/2008 10,875 49,387 -29,622 -269 30,371

Management Report

I. Main events

Over this period of the first six months, two major events should be highlighted:

- a major development by external growth – by far the largest transaction in the young history of the group: acquisition of all the shares of BEBIG GmbH, the company's former principal European competitor, and

- the announcement and the implementation of a restructuring plan for the enlarged group's activities.

(1) External growth - acquisition of BEBIG GmbH shares

February 2008: Announcement of an agreement with the Berlin-based German company Eckert & Ziegler AG (EZAG) concerning the acquisition of all the shares in BEBIG GmbH, an EZAG subsidiary, by IBt S.A. BEBIG was the unit within the EZAG group responsible for activities in the area of brachytherapy-based cancer treatment using permanent implants.

As a reminder: as part of this deal, IBt acquired the stock of BEBIG GmbH (including that of its affiliated entities, i.e. its subsidiaries in Spain and Italy as well as its French and Indian branches) for a total sum of EUR 23.4 million. The value of this deal was based on two factors:

- an EBITDA multiple of 5.5 (based on BEBIG's 2007 consolidated results), and

- the estimated value of the company's net working capital.

To finance this transaction, IBt issued a total of 6,750,000 new shares at a price of EUR 3.47 a share. These were entirely subscribed by EZAG. As a result, EZAG now holds 29.9% of all voting rights in the Group. The results of the regrouped entities were subjected to consolidation as of 1 March 2008.

This strategic operation has led to the doubling of the IBt group's size and puts it into a leadership position in its field of activities in Europe.

(2) Restructuring and integration

June 2008: Announcement of a plan for restructuring and integrating the Group's operations. The Group has two operational sites, one at Seneffe, the other in Berlin, both basically conducted the same operations.

To optimize operations, the plan foresaw:

(a) concentrating all Sales and Marketing activities, all R&D relating to the intellectual property held by IBt, and all headquarters operations (Finance, HR, IR, Legal, etc) in Seneffe; and

(b) concentrating all production activities in Berlin and terminating all production of InterSource and InterStrand implants.

These decisions have had two principal impacts:

(1) On the operational side: the intention to close down the manufacturing department at Seneffe implied mass redundancy. The procedure foreseen in such circumstances by the Renault Law ( loi Renault ) was immediately started, commencing with talks with employees' trade union representatives and followed by negotiations.

This whole procedure was completed by 15 July.

It led to 35 people (out of a total workforce of 108) being made redundant or not having their employment contracts renewed. All the costs relating to this restructuring are stated in the results for these first six months (cf. details below).

(2) On the commercial side: during this period, the Group was, on the whole, successful in limiting or minimizing the impact of these decisions on the supply and organization of its hospital customers.

However, because of the specific situation in the Dutch market, the company has sold, in August, the shares it held in its distributor, CurieMed b.v. to the partner already holding a stake in the company. The sale of shares will not generate any significant financial impact on the Group's results.

The scope of consolidation will be modified, with the results of this subsidiary no longer being consolidated as of 1 July.

II. Comments on the consolidated key figures

Income statement

Turnover resulting from the sale of products after margin rebates to distribution partners reached EUR 6.9 million, up 61% against the first six months of 2007. This increase is mainly explained by the integration of BEBIG sales, which account for 49% of the first six months' turnover.

Other operating income relates mainly to capitalized production, and to a major write-off (non-recurrent by nature).

Operating expenses break down as follows (compared with last year's figures):

(1) Cost of sales: EUR 3.71 million EUR (+ 73.9%)

(2) Sales and marketing expenses: EUR 2.0 million (+ 28.6%),

(3) General and administrative expenses: EUR 1.2 million (+ 59.5%),

(4) Research and development expenses: EUR 0.4 million (+46.3%)

(5) Other charges: EUR 0.1 million (-25.6%)

The increase in expenses is mainly attributable to the integration of BEBIG GmbH expenses.

EBITDA and Result before restructuring costs both show marked improvement.

Net profit was burdened with an exceptional charge of EUR 3.74 million relating to restructuring activities at Seneffe.

The main components of this provision are:

(1) For an amount of EUR 1.1 million: accelerated depreciation on tangible and non-tangible assets – production equipment,

(2) Write-downs (EUR 0.7 million) relating to inventories of raw materials and finished products;

(3) Expenses for staff and other charges (EUR 1.9 million) consisting of severance indemnities, contractual indemnities and miscellaneous provisions relating to the production site.

Balance sheet

Assets

Intangible assets (amounting to EUR 0.86 million) consist on the one hand of the net value of the technological processes amortized over their protected life; and on the other hand of the net value of development costs, amortized linearly over a period of five years.

Tangible assets, net of accumulated depreciation, have risen to EUR 8.43 million. The main components are: EUR 2.09 million for the Seneffe site and buildings and EUR 1.11 million for equipment (production machines, etc). The accelerated depreciation for the equipment assets has – as stated above – been fully provided for in the restructuring costs.

Inventories have risen to EUR 2.04 million, of which EUR 0.7 million have been subjected to a write-down in value. Receivables within one year have risen to EUR 6.38 million. Cash and cash equivalents have risen to EUR 2.99 million.

Liabilities

Equity amounts to EUR 30.37 million and breaks down into capital of EUR 10.88 million, issue premium of EUR 49.38 million from which the loss for the financial year (after appropriation of the result) and the deferred loss totaling EUR 26.45 million are deducted.

The amount of the provisions recorded in the balance sheet is EUR 4.65 million The main component is the provision made for restructuring (EUR 3.74 million).

Total debts have risen to EUR 13.37 million. The EUR 6.35 million total for amounts payable after one year breaks down into four items:

(1) for EUR 2.8 million: a debt arising from a 3 year loan provided by Eckert & Ziegler as part of the deal involving the purchase of shares in BEBIG GmbH;

(2) for EUR 1.6 million: asset retirement obligation on Berlin site;

(3) for EUR 1.2 million: related to amounts payable received in connection with the financing of R&D projects by the Walloon Regional Government. It should be noted that the effective repayment of these amounts remains dependent on certain conditions being met;

(4) for EUR 0.3 million: debt corresponding to the financing of the acquisition of equipment by leasing.

The amounts payable within one year are made up of trade debts (EUR 2.80 million), tax and social security debts (EUR 0.72 million), debts maturing during the year (EUR 1.85 million) and other debts (EUR 1.63 million) mainly coming from the new German subsidiary BEBIG GmbH.

III. Outlook

The BEBIG GmbH acquisition at the end of February has had a profound impact on the Group's outlook.

In its enlarged form, the IBt Group has now become a major European player in its specific field, with a wider revenue base for financing its sales, development and marketing expenses. IBt is today engaged in nearly all major markets with its subsidiaries in France, Germany, the United Kingdom, Belgium, Italy and Spain, and via an extensive network of distributors. The main objective for the coming quarters will be for IBt to finalize its integration plan.

With regard to its strategic future development, IBt currently holds a call option on certain assets of the Eckert & Ziegler group. These assets relate essentially to the so-called afterloader division of the company (note: afterloaders are medical device equipments that allow to perform cancer treatment by brachytherapy with usage of temporary implants instead of permanent implants). The decision on whether or not to exercise this option will be taken in the coming months.

IBt confirms its outlook of posting in 2008 its first annual profits before restructuring charges.

Declarations – Art.13 of R.D. of 14.11.2007

Mr. Andreas Eckert, Chairman of the IBt Board, and Mr. François Blondel, CEO, Managing Director,

declare that to the best of their knowledge:

a. The intermediate report contains a faithful presentation of significant events occurring over the first six months of the 2008 financial year, and, as the case may be, major transactions between related parties, and of their impact on the summary financial information.

b. the summary financial information prepared in conformity with the applicable accounting standards though without being subjected to a review by the external auditor, gives a true and fair view of the capital, the financial situation and results of the issuer and the consolidated subsidiaries of the Group.

For any additional information:

Mrs. Laurence Goemaere

Investor Relations Manager

IBt s.a.

Tel: [phone]

E-mail: [e-mail]

Internet: www.ibt.be

[meinolf67]

nterim Trading update - Q3, 2008

EMBARGO until Wed. Nov. 19, 2008 - 17h40

- Revenues 11.1 million EUR + 67 %

- EBITDA 2.7 million EUR + 270 %

- Net Income (before restructuring charges) + 0.9 million EUR

- External growth - two recent acquisitions: finalized

- Outlook confirmed

CONSOLIDATED KEY FIGURES

(in '000 EUR)

YTD Sep 2008

YTD Sep 2007

Variation
(in %)

Revenues 11.131 6.658 67%
Cost of Goods -5.193 - 5.053 3%
Gross Margin 5.937 1.605 270%
EBITDA 2.742 -692 N/A
EBIT 1.624 -2.054 N/A
Financial result -202 -77
Taxes -444 -108
Net Income before restructuring 880 -2.429 N/A
Impact restructuring costs -3.740 0
Net Income -2.859 -2.429


Produced with reference to IFRS standards, the figures in the above table, expressed in thousands of EUR, are consolidated but not audited.

EBITDA = Earnings Before Interest, Taxes, Depreciation and Amortization

Preliminary comment - Comparability

It must be pointed out that the comparability of the Q3 2008 and Q3 2007 figures is limited by the fact that the group's scope of activity has changed considerably between these two periods. More precisely:

(1) on the one hand, the scope of the Group's activities was reduced by the relinquishment of the direct sale activities in the USA, which was decided in September 2007, along with the closing of the US subsidiary and the cessation of certain production activities in Belgium (Pd-103 implants),

(2) on the other hand, this scope has been widened by the consolidation of the activities of BEBIG GmbH since 29 February 2008, following the acquisition of the shares of this company at the end of February 2008.

Income statement

Turnover, representing the income generated by sales in Europe of radiotherapeutic implants associated with I-125, rose by a solid 67% compared with the same period in 2007, whilst the increase in the cost of goods sold was limited to 3%. Other operating charges break down into sales and marketing expenses (EUR 3.92 million), general and administrative expenses (EUR 1.97 million) and research and development expenses (EUR 0.62 million). Other operating revenues and costs contributed positively for an amount of EUR 2.2 million. These relate to capitalized production and debt forgiveness, items that are by nature non-recurrent and non-cash. Both EBITDA and Result before restructuring costs show marked improvement. Net income was burdened with an exceptional charge relating to the restructuring of the activities of the group in Seneffe for an amount of EUR 3.74 million. This charge was detailed and booked in the H1 results.

COMMENTS AND PROSPECTS

As demonstrated by the Sept. YTD results of the group, the acquisition of BEBIG GmbH in Feb. 08 and the ensuing merge of the activities of the two companies has considerably modified and improved the group's prospects. Today, the group indeed holds a clear leadership position in its field in Europe and is now active on practically all major markets either directly through its subsidiaries (in France, Germany, UK, Belgium, Italy and Spain) or through its wide distributor network.

The group also continues to expand its reach as highlighted by the most recent successes in Spain (cfr press release of Sep 2), and the potentially important joint venture in Russia (cfr press release of Oct 3).

On the strategic front, IBt has also further pursued the reshaping of the scope of its activities. Recently (cfr press release Oct 14), the group has announced the acquisition of two additional businesses, both in its "core business" (i.e. the treatment of cancer by brachytherapy) while at the same time representing a diversification into "temporary brachytherapy" (i.e. the treatment of cancer by using temporary internal irradiation). Thanks to this investment, IBt can now offer an alternative cancer treatment option to patients suffering not only from prostate but also head, neck, gynecological or eye cancers. In this latest application, IBt holds a world dominant position by offering "high tech" therapy utilizing Ru-106 plaques.

These acquisitions have now been approved and will be consolidated from Nov. 30 thus contributing positively to the results of the group already in 2008.

Based on these positive developments, the expected low correlation of the activities of the group with the state of the global economy, and a historical record month for implants sales booked in October, IBt looks with confidence toward its future development and growth.

[meinolf67]

Embargo until 17h40 (Brussels time)
Jan 5, 2009

Change in the structure of Voting Rights
Transparency Declaration

Seneffe - Jan 5, 2009
IBt - (Reuters: IBTH.BR - Bloomberg: IBTB BB)

IBt s.a., based in Seneffe, has received a "transparency declaration" dated as of December 30, 2008. This notification, made in accordance with applicable regulations, has an important impact on the structure of the voting rights in the company.

As reminder :

Voting rights within IBt are exercised by two categories of securities:

- Regular IBt Shares: 17.554.354 outstanding shares
- Beneficiary Shares: 5.025.000

The Regular IBt Shares are listed on Euronext.

The Beneficiary Shares are not listed. They give no rights to dividends, nor to surplus in the case of liquidation but they do entitle their holder to vote during General Assemblies of shareholders. At the time of the incorporation of the company, 5 million Beneficiary Shares 'A' were issued to the founders of IBt s.a. and held through a US partnership.

As per the declaration, a call option (the right to acquire) the existing 5.000.000 Beneficiary Shares 'A', representing 22.1 % of the total voting rights in the company, has been transferred by Eckert and Ziegler AG ("EZAG") to SMI Steglitz MedInvest ("SMI"), a German investment firm.

SMI Steglitz MedInvest has confirmed its intention to immediately exercise this call option. The relevant Transparency Declaration is expected in the coming days.

Additionally, the company has been notified of the existence of a "cross call and put option" agreement signed between SMI and EZAG. Under the terms of this last agreement and in the event SMI exercises its call option and therefore acquires the Beneficiary Shares from the founders, then EZAG will have the right to acquire these Beneficiary Shares from SMI and SMI will have the right to sell such Beneficiary Shares to EZAG.

Contacts
François Blondel, CEO, Administrateur Délégué
Laurence Goemaere, Investor Relations Manager
Tel: [phone]
E-mail: [e-mail]

[meinolf67]

Embargo until 17h40 (Brussels time)

January 30, 2009

New Transparency Declaration

Seneffe - January 30, 2009

IBt - (Reuters: IBTH.BR - Bloomberg: IBTB BB)

IBt s.a. has today received "transparency declarations" dated as of January 29, 2009.

These notifications, made in accordance with applicable regulations, are in confirmation of the transaction previously announced by Press Release on January 5, 2009.

As a result, voting rights within IBt today break down as follows:

Floating - Euronext

38,5%

Regular Shares
Reference shareholders 9,4% Regular Shares
Eckert & Ziegler AG 29,9% Regular Shares
SMI Steglitz MedInvest 22,1% Beneficiary Shares

Total 100 %


As reminder :

The Regular IBt Shares are listed on Euronext.

The Beneficiary Shares are not listed. They give no rights to dividends, nor to surplus in the case of liquidation but they do entitle their holder to vote during General Assemblies of shareholders.

[R-BgO]

Annual Results - 2008

Seneffe - Belgium, 20 March 2009 - EMBARGO until 17.40

IBt (Reuters: IBTH.BR - Bloomberg: IBTB BB) publishes results for the year ending 31 December 2008

- Turnover EUR 17.2 million + 115 %
- EBITDA EUR 3.8 million + 567 %
- Net result (before restructuring costs) EUR 1.1 million
- Outlook 2009 - strong sales increase expected + 50 %

I. Key operating facts during 2008

- February - Acquisition and consolidation of the activities of the Eckert & Ziegler AG group in the field of brachytherapy by permanent implants (I-125 implants).

- June - Reorganization and restructuring of the group's activities. Ending of production of brachytherapy implants at the Seneffe, Belgium site.

- Commercial development in Spain (announcement of the signature of contracts with five hospital centers in September) and launch of the negotiations for the setting up of a Joint Venture in Russia (October)

- November - Acquisition of the activities of the Eckert & Ziegler AG group in the field of temporary brachytherapy (Rh-106 ocular implants and "afterloader" equipments with Co-60 and Ir-192 sources).

II. Consolidated key figures

Preliminary remarks

(1) The comparability of the figures between the 2008 and 2007 financial years is affected by the major change in the scope of the Group's activities between these two periods. Readers are reminded that the consolidation scope was considerably enlarged in 2008 by the impact of two operations: first the consolidation (since 1st March 2008) of the permanent brachytherapy activities of BEBIG GmbH, and then, following the acquisition of the activities of the Eckert & Ziegler group in the field of temporary brachytherapy, the consolidation of the results of this acquisition starting from 1st December 2008.

(2) As published earlier (cf. Press release of 19 March 2009), indemnification claim proceedings are currently ongoing between IBt s.a. and Eckert & Ziegler AG. This process is currently well under way and will ensue, if

successful, in no impact on the results of the company.

(in EUR '000)

FY2008

FY2007

Variation
Sales - Turnover 17,240 8,003 + 115%
Gross margin 9,477 1,116 + 749%
EBITDA 3,896 584 + 567%
EBIT 2,397 -241 n/a
Financial result -719 262 n/a
Taxes -553 -96 - 476%
Minority interests -40 -212 - 81%
Net profit/(loss) before restructuring costs 1,085 -287 n/a

Restructuring costs -3,766 -8,333
Net profit/(loss) -2,681 -8,620 + 69%


The figures in this table, expressed in thousands of EUR, are the consolidated results of the IBt group.

(1) EBITDA = Earnings Before Interest, Taxes, Depreciation and Amortization
(2) EBIT = Earnings Before Interest & Taxes
(3) The data relating to the 2007 results relate to the continued activities.

The turnover figure, consisting of the sales income from the sales in Europe of radiotherapeutic implants associated with I-125 and, since 1 December 2008, the first sales in the field of temporary brachytherapy ("afterloader" equipment and ocular implants) has more than doubled compared with the same period in 2007. Sales have advanced on all markets in which the group is active, but with particular success in Spain and Russia.

Operating expenses are divided between sales and marketing expenses (EUR 6.02 million), general and administrative expenses (EUR 2.87 million) and research and development expenses (EUR 0.26 million). The other operating income and charges have made a positive contribution (EUR 2.07 million) to earnings. This item relates essentially to the abandonment of a receivable, an element that is non-recurrent and non-cash by nature.

The financial result has been impacted by a foreign exchange loss related to GBP-denominated receivables and by the sharp depreciation of this currency during the past quarter. Minority interests relate to the third-party holding in the Dutch distribution subsidiary CurieMed b.v., Readers are reminded that IBt sold its shares, and the results of this entity left the consolidation scope, from 1 July 2008.

All earnings levels have made clear advances, at times spectacularly.

Gross Margin and EBITDA both ended up sharply, reflecting the clear improvement in the cost of producing permanent brachytherapy implants following the restructuring of the group's activities. Expressed in percentage terms, the gross margin is improving, reaching 55% for the year as a whole.

Both EBIT and net profit/(loss) before restructuring costs have turned positive for the first time since the company was founded. Net profit/(loss) itself has been affected by a non-recurrent expense, mainly non-cash, due to the restructuring of the Group's activities at Seneffe. This is detailed and included in the first half earnings results.

III. Comments and Outlook

2008 marked a clear turning point in the group's history in terms of its strategic development.

During this year indeed, the company's profile and field of action were both dramatically changed. External growth has enabled IBt, until then a specialized company proposing a treatment limited to early stage prostate cancer on the European market, to become today a group three times larger, proposing alternative treatments for a wider range of cancer tumors and distributing its products worldwide. IBt Bebig today occupies a clear lead position on its market segment.

Commenting on the group's results, François Blondel, CEO of the IBt Bebig group, declared: "Integration of the two groups' activities is now practically terminated. The evolution of earnings is tending to demonstrate the pertinence of the strategic choices we made and of our investment decisions. The figures already speak for themselves: we have clearly advanced at every earnings level", adding that: "beyond the figures, we are particularly proud to be able to say that the products manufactured and sold by the IBt Bebig Group will have contributed, during 2008 alone, to saving the lives of more than 5.000 people around the world ... and that we are hoping to be able to increase the number of persons whose lives we will help to save to well over 7.000 men and women in 2009..."

Outlook for 2009

Looking forward, the deterioration of the global environment calls for a certain prudence in making forecasts.

However, given that this deterioration is not affecting the group's activities, and based on the excellent operating results recorded during the final quarter of 2008, the group resolutely looks towards its future development and growth with clear optimism.

Turnover is expected to increase further and grow by over 50% in 2009. The group is also anticipating recording its first net profit.

During the coming quarters, IBt will be pursuing a strategy of both internal and external development aimed at growing a group with a strong identity and constituting the indisputable reference in the field of treatment of cancer by brachytherapy.

Forward looking Statements:

The press release contains qualifications as well as forward-looking information and estimates concerning the company's future performance. It can contain words that anticipate the future development. The declarations and estimates are based on various suppositions and assessments of risks, uncertainties and other factors, which appeared reasonable at the time they were made but which may or may not turn out to be correct. Events are not predictable and can depend on factors lying outside the control of the company and which can turn out significantly differently to what had been anticipated.

Financial calendar

- Annual report - available end-April
- Q1 2009 - business update - 27 May
- General Meeting - 1 June
- H1 2009 results - 31 August

Auditor's report

The statutory auditor has confirmed that, at the present stage of its works, it does not have cognizance of any elements which would significantly modify the accounting information given in the present press release, with the exception of the information given under "Preliminary remark (2)".

About IBt Bebig

The core business of the IBt Bebig group is "cancer treatment".

Its specificity is the treatment of cancer by brachytherapy. Brachytherapy is a technique which consists of placing a sealed implant containing a low dose of a radioactive isotope in the body, on either a temporary or permanent basis. The precise positioning of this implant at the very centre of the tumour makes it possible to effectively treat the cancer in a very localized manner and so reduce the secondary effects, increasing the patient's quality of life. Right now applications cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers.

The IBt Bebig group employs a little over 140 people and has entities in Germany, France, United Kingdom, Spain, Italy and India.

The company is listed on Euronext Brussels (Reuters: IBTH.BR - Bloomberg: IBTB BB) and is part of the Bel Small index.

Contacts

[R-BgO]

Embargo until 17h40

(Brussels time)
April 8, 2009

IBt s.a. - (Reuters: IBTH.BR - Bloomberg: IBTB BB) announces the successful conclusion of the negotiations on the creation of a Russian joint venture (see also press release of Oct2, 2008). The agreement related to the formation of "NanoBrachyTech", a Russian company based in Moscow, was signed today by the three parties involved.

The new company will focus on innovative technologies for the treatment of cancer by brachytherapy in the Russian Federation. The first projects of the joint venture will encompass (1) the acquisition and/or development of the technologies related to radioactive nanosources, and (2) the launch of an R&D program related to the usage of brachytherapy for the treatment of liver cancer. "This joint venture represents a very important step in our strategic development of the brachytherapy technique, both in terms of geographical market coverage and in extending the type of pathologies that can be treated by brachytherapy" stated Mr.François Blondel, CEO of IBt Bebig. "It is also the clear recognition by the Russian Federation of the leadership role that IBt Bebig plays in this specific market segment of the cancer treatment" he added.

IBt is holding a 15% equity stake in the joint venture in return for its contribution in kind, committing to provide access to its technology, know-how and intellectual property portfolio. "The next step is the expected signature of a global "Investment Agreement" that will serve as the framework for the future technology transfers between IBt Bebig and NanoBrachyTech. We expect these agreements to generate significant revenues for the group, starting already in 2009", he concluded.

About the three partners:

(1) Rusnanotech, or the "Russian Corporation of Nanotechnologies", is a State Fund corporation with a budget of 5 Bio $. Rusnanotech selects promising spheres for investment based on long-term forecast developed by leading Russian and world experts. It supports only the most competitive projects. It co-invests in nanotechnology projects that have high potential for commercial or social benefit. The Corporation organizes the scientific, technical and investment due diligence. It takes part in long-term investment projects and provides maximum administrative support to its investees.
It is the main partner in the joint venture. It will provide funding together with production equipments, see www.rusnano.com
(2) Santis Ltd is a Russian private company that has, over the last few years, together with its affiliates, succeeded in developing significantly the Russian market for usage of radioactive sources.
(3) About IBt Bebig. The core business of the IBt Bebig group is cancer treatment. Its specificity is the cancer treatment by the brachytherapy technique, whether achieved through permanent implants or temporary brachytherapy. The IBt Bebig group currently has entities located in Germany, France, the UK, Spain, Italy and India. The Headquarters are based in Seneffe, Belgium. The company is listed on Euronext Brussels (Reuters: IBTH.BR - Bloomberg: IBTB BB).

Contacts :

Investors Relations
Tel: [phone]
E-mail: [e-mail]
Internet: www.ibt-bebig.eu

[R-BgO]

IBt s.a., Seneffe, Belgium - May 15, 2009

(Reuters: IBTH.BR - Bloomberg: IBTB BB)

The company has been notified of a decision taken by the President of the Tribunal of Charleroi.

The judge, based on a request introduced by two independent Directors of IBt (MM. Jean-Pierre Delwart and Claude Onkelinx), has decided to temporarily deprive Mr Andreas Eckert from his position of Chairman of the Board of Directors until the case about the mandatory takeover, ordered by the CBFA, is resolved (see previous Press Releases and communications on this subject).

The Court has also decided to temporarily appoint Mr John Carden as new Chairman of the Board of IBt. Mr Carden is one of the founders of the company and has served as a Director of IBt since the incorporation of the company in 1996.

The decision of the Court is taking effect immediately.

As this decision was taken under the procedure of "extreme urgency" (hearings limited to the arguments of one party), the case will be heard on a contradictory basis in the coming days.

About IBt Bebig.

The core business of the IBt Bebig group is cancer treatment. Its specificity is the cancer treatment by the brachytherapy technique, whether achieved through permanent implants or temporary brachytherapy. The IBt Bebig group currently employs over 140 people and has entities located in Germany, France, the UK, Spain, Italy and India. The Headquarters are based in Seneffe, Belgium. The company is listed on Euronext Brussels (Reuters: IBTH.BR - Bloomberg: IBTB BB).

[R-BgO]

Embargo until 17h40
(Brussels time)
Monday - June 22, 2009

IBt s.a., Seneffe, Belgium - 22 June 2009

IBt s.a. announces the signature of two major contracts with NanoBrachyTech, a joint venture in which IBt holds a 15% equity stake. The contracts cover:

(1) Purchase of production assets agreement

NanoBrachyTech is acquiring a number of production assets using the latest technology developed by the IBt Bebig group in the brachytherapy field.

(2) Technology transfer license and exclusive distribution rights agreement

NanoBrachyTech is also acquiring rights to have access to and usage of intellectual property, know-how and technologies developed and owned by IBt Bebig, together with commercial exclusive rights for distribution in Russia, Ukraine, Belarus and Kazakhstan territories.

The delivery of the production lines will include the installation of an I-125 brachytherapy microsources production line. The installations are scheduled to take place according to defined milestones and expected to be fully completed by the end of 2010.

The technology transfer agreement is valid for an initial period of 20 years. It provides for upfront and milestones payments to be made to IBt, together with "production volume" based royalties thereafter.

"We are very pleased with this strategic development in a part of the world that represents a key market for the IBt Bebig group. We believe that there is an enormous potential for increased usage of the brachytherapy technology" stated Mr. François Blondel, CEO of IBt Bebig. "The revenues generated by these contracts will reach well over 10 million EUR over the following two years alone, and they will also significantly contribute to our net earnings already this year in 2009" he added.

NanoBrachyTech is a recently formed (see our Press Release of April 8, 2009) joint venture between Rusnanotech Corp, Sanlis ltd and IBt s.a. NanoBrachyTech focuses on (1) the development of innovative nano technologies for the treatment of cancer by brachytherapy in the Russian Federation, (2) manufacturing of microsources and nanostructures for the delivery of medical treatment.

About Rusnanotech

The main partner in this joint venture is Rusnanotech (the "Russian Corporation of Nanotechnologies"), a State Fund Corporation with a budget of 5 Bio $. The Corporation co-invests in projects that have high potential for commercial or social benefits in the Russian Federation. It selects and supports only the most competitive projects based on long-term forecast developed by leading Russian and world experts. It takes part in long-term investment, organizes the scientific, technical and investment due diligence and provides maximum financial and administrative support to the companies it invests in.

About IBt Bebig

The IBt Bebig group is active in the Health Care sector.

The core business of the IBt Bebig group is cancer treatment by radiation technology. Its specificity is the cancer treatment by the brachytherapy technique, whether achieved through permanent implants or temporary brachytherapy by usage of implants, plaques or catheters. The IBt Bebig group today employs over 140 people and has subsidiaries or offices in Germany, France, the UK, Spain, Italy and India. Its headquarters are located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH.BR - Bloomberg : IBTB BB).

Contacts
François Blondel, CEO
Laurence Goemaere, IR Manager
Tel: [phone]
E-mail: [e-mail]

Web Site: www.ibt-bebig.eu

[R-BgO]

1,000th patient
Treated with I-125 implants
at Christie Hospital, Manchester - England

IBt s.a., Seneffe, Belgium - July 9, 2009

Christie Hospital located in Manchester, United Kingdom, is one of Europe's leading cancer centers, treating over 40,000 patients a year and is an acknowledged leader in international research. The prostate cancer brachytherapy program is the largest in the U.K and has just treated its 1,000th patient using iodine-125 permanent brachytherapy implants.

Cooperation between Christie Hospital and the IBt Bebig group dates back to 2006. Dr. James Wylie, Radiation Oncologist, commented: " Our excellent working relationship with IBt Bebig has greatly facilitated this cancer treatment program and we now plan to be collaborating with IBt Bebig on the development of new products".

The brachytherapy treatment of early stage prostate cancer - for which IBt Bebig is today recognized specialist in Europe and leader in its segment - is being applied increasingly across the continent, where more than 135,000 new cases of prostate cancer are diagnosed every year. Of this number, just over 12,000 men are treated with permanent brachytherapy implants. For comparison purposes, this number is four times higher in the USA.

[R-BgO]

Seneffe - Belgium, July 28, 2009 - EMBARGO until 17:40, Brussels Time.

- Very strong growth trend and record results during H1,09
- Revenues to exceed 16 millions EUR
- Gross Margin to reach 9 millions EUR
- EBIT to be close to 3.2 millions EUR

Preliminary reporting for the IBt Bebig group on the results for the first six months of 2009 indicates a very robust growth in revenues and strong profitability of the group.

Current reporting indicates that Revenues have topped 16 million EUR, generated by the sales of radiotherapeutic I-125 permanent brachytherapy implants used for the treatment of prostate cancer and by strong sales of Co-60 temporary brachytherapy equipments (usually referred to as "afterloaders") allowing to treat primarily gynecological, head or neck cancers. Sales of Ru-106 ophthalmic plaques also pursued their progression. In addition, the total income was significantly boosted by the first revenues generated by the contracts signed in Russia earlier this year. In total, the revenues recorded over the elapsed period represent well over the double of the revenues recorded last year over the same period.

The H1,09 group operating profit (EBIT) will be close to 3.2 million EUR, i.e. representing a 20% margin when expressed in proportion to revenues. Net income is forecasted to reach close to 2.7 million EUR, i.e. a "Net Income margin" in excess of 15% during the first half year of 2009.

Based on these achievements and the outlook for the remainder of the year, the company expects to review and increase significantly the guidance for the year 2009 that was provided at the time of the Q1 results publication. Final and detailed financial report for the first half of 2009 as well as review of the 2009 outlook will be published by press release on August 31, after closing of the Euronext - Brussels Stock Exchange.

[R-BgO]

guter Start:

http://www.euronext.com/trader/summarizedmarket/stocks-2593-…

[R-BgO]

IBt - International Brachytherapy s.a. : TRADING UPDATE - Q3, 2009

EMBARGO until Oct 28th, 2009 17h40 - Brussels time

- Record Results – YTD,09

- Gross Margin 13.5 million EUR + 128 % - EBITDA 5.8 million EUR N/A - Net Profit 3.9 million EUR N/A

- Guidance for FY 2009 revised upwards again

TRADING UPDATE - Q3, 2009 - Seneffe, Belgium

CONSOLIDATED KEY FIGURES

(in '000 EUR)

YTD

YTD

Variation
sept-09 Sep 2008 (1) (in %)

Turnover 23.708 11.131 113%
Cost of Goods - 9.020 - 5.193 -74%
Gross Margin 13.510 5.937 128%
EBITDA 5.784 - 1.310 N/A
EBIT 4.366 - 2.335 N/A
Financial result -408 -101
Taxes -60 -403
Net profit 3.898 - 2.879 N/A

(1) It should be pointed out and reminded that the scope of consolidation has significantly changed during the year 2008. The comparability between the two periods presented in this trading update is therefore impacted. In short: since March 1st 2008, the group is consolidating the results of Bebig GmbH (permanent brachytherapy activities) and, following their acquisition in November 2008, the group is further consolidating the results of the temporary brachytherapy activities since Dec 1st 2008. On the other hand, in July 2008, the group has divested from production activities in Belgium and sold its stake in CurieMed b.v., its then Dutch subsidiary.

(2) The figures in the tables included in this report present the group's financial statements with reference to IFRS standards. They are consolidated but not audited.

(3) EBIT(DA) = Earnings Before Interest, Taxes, (Depreciation and Amortization)

The Turnover, representing the income generated by sales of temporary brachytherapy equipments (i.e. Co-60 and Ir-192 afterloaders ), ophthalmic plaques and permanent brachytherapy I-125 radiotherapeutic implants, rose by a solid 113 % compared with the same period in 2008. Revenues generated by the Russian project, representing a little under 15% of the total turnover, also contributed to the overall growth. It is expected that this important development will further positively fuel the results of the group over the following years. Once the production has started in Russia, IBt Bebig will benefit from a stream of royalties generated by NanoBrachyTech, the joint venture developped together with Rusnano, the Russian State fund and in which IBt Bebig holds a 15% stake.

Operating charges break down into sales and marketing expenses (EUR 4.68 million), general and administrative expenses (EUR 3.91 million) and research and development expenses (EUR 0.80 million). Other operating revenues and costs contributed positively for an amount of EUR 0.25 million.

Profitability indicators demonstrate strong performance with all lines of results setting new historical record levels for the group:

- the Gross Margin, topping EUR 13.5 million on a YTD basis, reflects the clear improvement in the manufacturing cost structure following the reorganization of the group's activities. This gross margin has continued to progress over the course of the year. As expressed in percentage terms, it now reaches 60%. - the EBITDA result, amounting to EUR 5.8 million, represents a solid 24% margin when expressed in proportion to revenues and yields strong cash flow generation, - the EBIT result and the Net Profit are both hitting record highs.

Comments and Outlook for 2009

These results are clear evidence of the resilience of the activities of the group in an otherwise globally very challenging environment. The different lines of products, activities or territories have all contributed to the growth recorded.

This set of record results also clearly demonstrates the successful turnaround of the group after a strategic move that was initiated in the fall of 2007. IBt Bebig today occupies a key market position in the brachytherapy segment of the cancer treatment by radiation field, with a strong and well balanced portfolio of products.

[R-BgO]

28.12.2009 19:51
DGAP-Adhoc: Eckert & Ziegler unterbreitet freiwilliges Übernahmeangebot für IBt

Eckert&Ziegler unterbreitet freiwilliges Übernahmeangebot für IBt

Eckert&Ziegler Strahlen- und Medizintechnik AG / Übernahmeangebot

28.12.2009

Veröffentlichung einer Ad-hoc-Mitteilung nach § 15 WpHG, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

-------------------------------------------------------------------- -------

Berlin, den 28. Dezember 2009. - Die Eckert&Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) hat heute bei der belgischen Finanzaufsicht CBFA den Antrag gestellt, ein öffentliches Übernahmeangebots in bar für alle noch ausstehenden 10,96 Mio. Aktien des am Brüssler EURONEXT gelisteten Medizingeräteherstellers International Brachytherapy (IBt) unterbreiten zu dürfen. Pro Aktie bieten Eckert&Ziegler und Mitinitiator und IBt-Aktionär Steglitz Medinvest (SMI) dabei 3,64 EUR. Sollte die Offerte vollständig angenommen werden, hätte sie ein Volumen von ca. 40 Mio. EUR. Der Prospekt und die Angebotsunterlage werden veröffentlicht, sobald diese von der CBFA zugelassen sind, was Ende Januar 2010 erwartet wird.

Mit dem freiwilligen Übernahmeangebot gegen Barzahlung wollen Eckert & Ziegler und SMI einen knapp zwölfmonatigen Rechtsstreit um die Beherrschung von IBt beenden. Im Interesse einer unkomplizierten Lösung haben sich die Bieter dabei für die freiwillige Umsetzung einer -- momentan noch gerichtlich angefochtenen -- Anordnung der belgischen Finanzaufsicht vom 28.04.2009 und 27.05.2009 entschieden. Sie sah vor, dass Eckert&Ziegler und SMI gemeinsam ein Pflicht-Übernahmeangebot für 3,47 EUR pro Aktie unterbreiten. Um zudem sämtliche Forderungen zu erfüllen, die in einem parallelen anhängigen Rechtstreit des IBt Aktionärs Creafund II SCA gegen Eckert&Ziegler und SMI erhoben werden, haben Eckert&Ziegler und SMI den ursprünglich geforderten Preis von 3,47 EUR pro Aktie um die eventuell anzuwendenden gesetzlichen Verzugszinsen auf 3,64 EUR pro Aktie erhöht.

[R-BgO]

Eckert & Ziegler beruft außerordentliche IBt Hauptversammlung ein

Berlin, 08.01.2010 - Die Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) hat offiziell beim bestellten Wirtschaftsprüfer des öffentlich gelisteten Belgischen Seedproduzenten International Brachytherapy S.A. (IBt) die schnellstmögliche Einberufung einer außerordentlichen IBt Hauptversammlung gefordert. Der einzige Tagesordnungspunkt auf der Agenda ist ein Wechsel im IBt Verwaltungsrat. Das Verwaltungsratsmitglied H&H Capital Management BVBA, vertreten durch den Alleingeschäftsführer und Creafund Abgesandten Herman Wielfaert soll durch einen Repräsentanten der Steglitz Medinvest UG (SMI), welche zusammen mit Eckert & Ziegler am 28. Dezember 2009 ein öffentliches Übernahmeangebot für IBt unterbreitet hat, ausgetauscht werden. Die in Berlin ansässige Steglitz Medinvest, die ca. 22% der IBt-Anteile hält, ist bislang noch nicht im IBt Verwaltungsrat vertreten.

"SMI ist am Übernahmeangebot beteiligt und ein großer Anteilseigner von IBt, somit ist es selbstverständlich, dass SMI zumindest einen Vertreter in den Verwaltungsrat entsendet", erklärte Dr. Andreas Eckert, Vorstandsvorsitzender von Eckert & Ziegler. "Auf der anderen Seite hat Creafund mit beträchtlichem Aufwand und Geld eine Klage gegen Eckert & Ziegler und SMI angestrengt, wonach diese ein Übernahmeangebot in bar für alle IBt Aktien unterbreiten sollen. Jetzt, da wir dieses freiwillig, mit erheblichem Aufwand und in Übereinstimmung mit Creafunds Forderungen erfüllen, erwarten wir, dass Creafund das Angebot annimmt und seinen Verwaltungsratssitz für den neuen Mehrheitsgesellschafter räumt."

Eckert & Ziegler besitzt derzeit ca. 29% der IBt Aktien und ist im Verwaltungsrat mit zwei Vertretern präsent. Vier weitere Mitglieder sind unabhängig. Drei Mitglieder des Verwaltungsrates werden mit dem IBt Vorstand besetzt. Zusammen mit dem SMI Vertreter wird der Verwaltungsrat aus zehn Mitgliedern bestehen, was der maximalen Anzahl gemäß der IBt Satzung entspricht.

[R-BgO]

For immediate release - January 15, 2010

Seneffe - Belgium, January 15, 2010, The Board of Directors of IBt Bebig group (Reuters: IBTH.BR - Bloomberg: IBTB BB) announced today that it has appointed Petercam S.A. as its financial advisor to assist the company in the framework of the mandatory takeover offer launched by the companies Eckert & Ziegler AG (EZAG) and SMI Steglitz (SMI) on all IBt shares.

The mission undertaken by Petercam for the company will consist of:

- The analysis of the situation, the offer and a preparation of a file on IBt Bebig taking into account in particular the relationship with the Bidders (EZAG & SMI) ;

- The assistance in the preparation and the drafting of the " memo in response", i.e. the document that the Board of Directors will make public, containing a motivated opinion on the offer (ref. to article 28 of Royal Decree of April 27, 2007).

The current and future relationships between the bidders and IBt Bebig are one of the elements that will be taken into account in the evaluation of the financial consequences of the launch of the offer on the interests of the company and on the interests of the stakeholders.

"This compulsory takeover bid represents of course a key moment in the life of our company. We are very pleased to have a firm like Petercam assisting us in the process as they are clearly one of the leaders in the sector of financial expertise service provider", commented François Blondel, Chief Executive Officer of IBt Bebig.

The company was furthermore informed that EZAG and SMI have requested the reopening of hearings, with the stated motivation to put an end to the ongoing litigation, in the trial which is still in process with the Court of Appeal of Brussels, in which EZAG and SMI oppose the CBFA and Creafund. The company has not been notified by the Court of Appeal of Brussels of the date on which a decision will be rendered.

[R-BgO]

Trading Update - Year 2009

Record Results

Embargo until 5:40 pm (Belgian time) – January 21, 2010

Very robust growth and Strong profitability in FY2009

- Sales EUR 32.5 million
- EBITDA to be close to EUR 8 million
- Net Profit to exceed EUR 4.8 million

Seneffe – Belgium, January 21, 2010, IBt Bebig (Reuters: IBTH.BR – Bloomberg: IBTB BB) has today announced its trading update for the results of the year 2009 based on preliminary reporting.

Operating Highlights of 2009

From an operating point of view, following items should be highlighted:

- In a growing number of emerging markets, the company encountered success in the promotion of its Temporary Brachytherapy MultiSource® solution – a world unique HDR (High Dose Rate) Co-60 afterloader equipment. This system allows for the efficient treatment of a number of different pathologies ranging from head, neck, brain or gynecological cancers. During the year 2009, the 100th hospital proceeded with the installation of a MultiSource®.

- Successful development of the group in Russia. Creation of a Russian joint venture, NanoBrachyTech, in association with RusNano, the State Fund of the Russian Federation. The JV, based in Moscow, will initially focus on innovative technologies for the treatment of cancer by brachytherapy. It is expected that this major development will yield up to EUR 20 million in revenues for the group over the life of the project.

- Towards the end of the year, the signature of a strategic alliance with Core Oncology, Inc. (USA) and currently one of the top four companies in the American market for Permanent Brachytherapy, represents another major project for IBt Bebig as this alliance could provide a unique opportunity to re-enter into a market that is roughly four times the size of the European market.

Preliminary Key Financial Results

Current reporting indicates that, boosted by a surprisingly strong fourth quarter, total sales for the year 2009 have reached an historical all-time high in the amount of EUR 32.5 million.

The source of revenues was evenly split between Permanent Brachytherapy and Temporary brachytherapy products. Approximately half of the total revenues were indeed generated by sales of I-125 (Iodine-125) radiotherapeutic implants, used for the treatment of early stage prostate cancer. The other half of the revenues related to sales of MultiSource® HDR Co-60 temporary brachytherapy equipments (usually referred to as afterloaders), Ru-106 (Ruthenium) ophthalmic plaques and therapy accessories. In addition, the total income was also boosted by revenues generated by the contracts signed in Russia earlier in the year.

Earnings before interest and taxes (EBIT) is reported to reach almost EUR 6 million for the year 2009, therefore more than doubling the amount booked in the previous year or EUR 2.4 million in 2008 (1).

On a Net Income basis, the company will also book its first annual Net Profit ever since IBt started its activities a little over than ten years ago. Net Profit for the year 2009 should exceed EUR 4.8 million compared to a net loss of EUR 2.7 million in 2008. This Net Profit will represent a margin exceeding 14% when expressed in proportion to revenues.

Finally, on the balance sheet side, IBt Bebig also ended up the year in a strong position with total cash exceeding EUR 9 million.

The company will provide its guidance for the year 2010 at the time of the release of the detailed financial report for the 2009 figures (on March 15, 2010).

Note (1): The comparability between the years 2009 and 2008 is somewhat reduced as the consolidation scope of the group was substantially modified (several acquisitions – Bebig GmbH and temporary brachytherapy activities – and divestitures, CurieMed bv.) during the course of the year 2008. The year 2009 is therefore the first full year in which the full benefit of the acquisitions is integrated and reported.

[GustavOemark]

!

Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users

[R-BgO]

IBt Bebig and Core Oncology Inc.

Discussions about possible Merger - Update

Embargo until 5:40 pm (Belgian time) - February 22, 2010

Seneffe - Belgium, February 22, 2010, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) announced today that following the initial US$ 2 million investment - in the form of a subordinated loan - made in November 2009 by IBt Bebig in Core Oncology, Inc., the two companies have entered into discussions about a possible merger of their activities.

The aim of these discussions was to come to some conclusion by the end of the first half 2010.

If these were not to be conclusive, then the US$ 2 million loan would be reimbursed to IBt Bebig at its maturity, i.e. June 30, 2010.

If the negotiations were to achieve a merger of the two groups, then the combined entity would result into a truly global World player in its market, highly focused and entirely dedicated to the treatment of cancer by Brachytherapy, and generating revenues well above EUR 45 million (or US$ 60 million).

Core Oncology and IBt Bebig are today perfectly complementary in terms of market coverage, as Core Oncology focuses on the North American market whilst IBt Bebig has no direct presence in the USA.

"Advanced discussions have been underway for some time. They could very well materialize in a matter of a few weeks or a few months; but, also, possibly, never. It all very much depends on the mutually satisfactory negotiation of a number of elements. The outcome of which is still uncertain at this stage", commented Francois Blondel, Chief Executive Officer of IBt Bebig. "But considering that a mandatory takeover bid will start this week on all IBt securities, we strongly felt important for all our shareholders to understand the strategic objective pursued and to know where we stand with our discussions".

About Core Oncology

Core Oncology was founded September 15, 2006 by the existing management of the brachytherapy business owned by Coloplast, formerly Mentor, for the sole purpose of enhancing the levels of service and continuing our pursuit of innovation within the field of Radiation Oncology. Our philosophy is to make our Customers and their trusted patients the focus of our business. Meeting their needs is our primary goal. This is how we derived our name Core Oncology, as our Customers and Patients are our center, our focus, our core.

On June 8, 2007, Core Oncology completed its acquisition of Mills Biopharmaceuticals LLC, the recently acquired brachytherapy division of Coloplast. Prior to this, the brachytherapy division was owned by Mentor Corporation. Initially formed in 1997, Mentor's brachytherapy division entered the radiation oncology market as the first company to offer both iodine and palladium brachytherapy sources. Since then the division has developed and successfully launched numerous innovative delivery technologies and services, including the Isoloader® workstation, prescription loaded needle services and proprietary cartridge systems for the Mick® applicator. This division has maintained a track record of strong year-on-year growth in a highly competitive market space.

The management team that has facilitated the growth and development of the brachytherapy division is the same team that now manages Core Oncology. This team has remained intact from the beginning of the business. We pride ourselves on the culture that we have established and the employee retention that has resulted.

[R-BgO]

IBt - International Brachytherapy s.a.Trading Update - Year 2009 - Record Results



Trading Update - Year 2009

Record Results

Embargo until 5:40 pm (Belgian time) � January 21, 2010

Very robust growth and Strong profitability in FY2009

- Sales EUR 32.5 million
- EBITDA to be close to EUR 8 million
- Net Profit to exceed EUR 4.8 million

Seneffe � Belgium, January 21, 2010, IBt Bebig (Reuters: IBTH.BR � Bloomberg: IBTB BB) has today announced its trading update for the results of the year 2009 based on preliminary reporting.

Operating Highlights of 2009

From an operating point of view, following items should be highlighted:

- In a growing number of emerging markets, the company encountered success in the promotion of its Temporary Brachytherapy MultiSource� solution � a world unique HDR (High Dose Rate) Co-60 afterloader equipment. This system allows for the efficient treatment of a number of different pathologies ranging from head, neck, brain or gynecological cancers. During the year 2009, the 100th hospital proceeded with the installation of a MultiSource�.

- Successful development of the group in Russia. Creation of a Russian joint venture, NanoBrachyTech, in association with RusNano, the State Fund of the Russian Federation. The JV, based in Moscow, will initially focus on innovative technologies for the treatment of cancer by brachytherapy. It is expected that this major development will yield up to EUR 20 million in revenues for the group over the life of the project.

- Towards the end of the year, the signature of a strategic alliance with Core Oncology, Inc. (USA) and currently one of the top four companies in the American market for Permanent Brachytherapy, represents another major project for IBt Bebig as this alliance could provide a unique opportunity to re-enter into a market that is roughly four times the size of the European market.

Preliminary Key Financial Results

Current reporting indicates that, boosted by a surprisingly strong fourth quarter, total sales for the year 2009 have reached an historical all-time high in the amount of EUR 32.5 million.

The source of revenues was evenly split between Permanent Brachytherapy and Temporary brachytherapy products. Approximately half of the total revenues were indeed generated by sales of I-125 (Iodine-125) radiotherapeutic implants, used for the treatment of early stage prostate cancer. The other half of the revenues related to sales of MultiSource� HDR Co-60 temporary brachytherapy equipments (usually referred to as afterloaders), Ru-106 (Ruthenium) ophthalmic plaques and therapy accessories. In addition, the total income was also boosted by revenues generated by the contracts signed in Russia earlier in the year.

Earnings before interest and taxes (EBIT) is reported to reach almost EUR 6 million for the year 2009, therefore more than doubling the amount booked in the previous year or EUR 2.4 million in 2008 (1).

On a Net Income basis, the company will also book its first annual Net Profit ever since IBt started its activities a little over than ten years ago. Net Profit for the year 2009 should exceed EUR 4.8 million compared to a net loss of EUR 2.7 million in 2008. This Net Profit will represent a margin exceeding 14% when expressed in proportion to revenues.

Finally, on the balance sheet side, IBt Bebig also ended up the year in a strong position with total cash exceeding EUR 9 million.

The company will provide its guidance for the year 2010 at the time of the release of the detailed financial report for the 2009 figures (on March 15, 2010).

Note (1): The comparability between the years 2009 and 2008 is somewhat reduced as the consolidation scope of the group was substantially modified (several acquisitions � Bebig GmbH and temporary brachytherapy activities � and divestitures, CurieMed bv.) during the course of the year 2008. The year 2009 is therefore the first full year in which the full benefit of the acquisitions is integrated and reported.

Control

The auditor has not reviewed any of the figures contained in this trading update.

Shareholders Calendar

The full set of Annual Results 2009 will be published by March 15, 2010
Trading Update 1Q-2010: by May 15, 2010
Annual General Assembly: June 7, 2010 (at 10:30 am)

[R-BgO]

For immediate release - March 9, 2010

Seneffe, Belgium, March 9, 2010. IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) announced today that, because of recent developments, the acceptance period for the takeover bid on all IBt securities by Eckert & Ziegler AG and SMI Steglitz Medinvest has been extended to 4:00 p.m., March 17, 2010.

[R-BgO]

Eckert & Ziegler: Wechsel im Management von IBt Bebig

Berlin, 24.03.2010 - IBt Bebig, eine Beteiligungsgesellschaft der Eckert & Ziegler AG (ISIN DE0005659700) teilte heute mit, dass François Blondel, CEO und das Unternehmen beschlossen haben, ihre Zusammenarbeit zu beenden.

François Blondel wird mit sofortiger Wirkung von all seinen Aufgaben und Verantwortungen innerhalb der Gruppe zurücktreten, sowohl als Direktor der IBt s.a. als auch ihrer Tochterunternehmen.

Dr. Edgar Löffler und Dr. Gunnar Mann, Direktoren der IBt, werden zukünftig das Tagesgeschäft verantworten. Sie werden die Verantwortlichkeiten von Herrn Blondel übernehmen und IBt gemeinsam in ihrer Funktion als Geschäftsführer leiten.


Der Vorstand

[R-BgO]

Eckert & Ziegler schließt Übernahmeangebot für IBt ab



Berlin, 24.03.2010. Die Eckert & Ziegler AG (ISIN DE0005659700) teilt hiermit das Ergebnis des IBt Übernahmeangebotes mit. Bis zum Ende der Annahmefrist am 17. März 2010 wurden dem Unternehmen 6.042.144 IBt Aktien, alle 25.000 IBt Vorzugsaktien Typ B sowie 120.440 IBt Optionsscheine zum Rückkauf angeboten.



Damit hält Eckert & Ziegler nun 12.635.594 IBt Aktien, 25.000 IBt Vorzugsaktien Typ B sowie 120.440 IBt Optionsscheine, was einem Anteil von 56% an den IBt Stimmrechten entspricht. SMI hält 5.000.000 IBt Vorzugsaktien Typ A, was einem Anteil von 22% an den IBt Stimmrechten entspricht. Wie in ihrer gemeinsamen Transparenzerklärung vom 6. Januar 2010 bekanntgegeben, unterbreiteten Eckert & Ziegler und SMI gemeinsam das Übernahmeangebot.



Bezahlung

Die Bezahlung der IBt Aktien, IBt Vorzugsaktien Typ B and IBt Optionsscheine erfolgt über die Zahlstelle KBC Securities am 7. April 2010 direkt an die Begünstigten oder über die jeweiligen Finanzinstitute.

[R-BgO]

30.03.2010 18:19
IBt sees sales growth slowing to 10 pct in 2010

BRUSSELS, March 30 (Reuters) - Belgian radiation-emitting implant maker International Brachytherapy said on Tuesday that it expected like-for-like sales growth to slow to 10 percent in 2010.

Sales shot up by 78 percent in 2009.

Chief Executive Gunnar Mann also told a news conference that the company did not envisage paying any dividend in the next couple of years.

[Syrtakihans]

Antwort auf Beitrag Nr.: 39.249.312 von R-BgO am 30.03.10 20:38:16

Warum unterschlägst Du die wesentlichen Informationen des heutigen Tages?

Die vorab vor dem Übernahmeangebot gemeldeten Zahlen zum GJ 2009 wurden bei weitem nicht erreicht. Umsatz beläuft sich auf nur 30,7 Mio. EUR, EBIT auf nur 5,4 Mio. EUR, und EPS nur auf 0,25 EUR/Aktie.

[R-BgO]

Antwort auf Beitrag Nr.: 39.249.499 von Syrtakihans am 30.03.10 21:07:23

Sorry, hatte ich nicht gesehen; muss ich mir bei Gelegenheit mal in Ruhe anschauen.

GB ist seit heute da.

[R-BgO]

Q1-2010 TRADING UPDATE
QUARTER AFFECTED BY EQUIPMENT SALES, BUT OUTLOOK CONFIRMED

Embargo until 5:40 pm (Belgian time) - May 3, 2010

Seneffe - Belgium, May 3, 2010, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB)
has today announced its Trading Update for the first quarter 2010 ending March 31, 2010.

MILESTONES OF THE FIRST QUARTER 2010

Shareholders perspective:
- The quarter saw the end of the Takeover bid process by Eckert & Ziegler, which
now owns 72% of all outstanding shares and 78.2% of voting rights (when acting in
concert with SMI Steglitz) over IBt. The quarter saw also a change in the management of the Group, with the resignation of François Blondel and the appointment of Dr. Edgar Löffler and Dr. Gunnar Mann, each in his capacity as Managing Director.

Operating point of view - Permanent Brachytherapy (largest products line):
- IBt Bebig signed early March a four years contract with the IMO group in Spain, to
supply IsoCord® - a unique needle loading station that enables the practitioner to
cut the seed chain in a safe and convenient way. The IMO Group is the largest
network of cancer treatment centers using radiotherapy techniques in Spain.
- Sales coming from Permanent Brachytherapy products were up from the first
quarter 2009, showing an ongoing demand for this very effective treatment option.

Operating point of view - Temporary Brachytherapy:
- Sales coming from Temporary Brachytherapy products were down during the first
quarter 2010, however in line as expected by the management. This decline is
caused by the delayed decisions in many hospitals for new projects during the most
critical phase of the world economical crisis. Whereas these projects affect the
current revenue, the company expects recovery of the sales activities over the next
quarters.

It should be noted that during this first quarter 2010, no revenue was recognized from the
Russian joint venture, however, with the project moving on as planned, it will significantly
contribute to the quarters to come.

CONSOLIDATED KEY FIGURES

Sales for this first quarter 2010, representing the income generated by the sales of
temporary brachytherapy equipments, i.e. HDR equipments using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders"), ophthalmic plaques and permanent brachytherapy I-125 (Iodine-125) radiotherapeutic implants and therapy accessories, reached EUR 6.3 million, compared to EUR 6.9 million in Q1-2009.

Earnings before interests and taxes (EBIT) reached EUR 0.8 million for this Q1-2010
compared to EUR 1.1 million in Q1-2009. While EBIT from ongoing operations is growing,the number is affected by settlement payments related to the resignation of the formerCEO.

Net profit reached EUR 0.8 million compared to a net profit of EUR 1 million in Q1-2009.

Total Equity of the group stood at EUR 34.3 million on March 31, 2010 versus EUR 30
million a year earlier.

IBt Bebig also maintained a solid financial situation, with Cash amounting to EUR 9.1
million end of March 2010. Net Debt stands at EUR 3.4 million.

The table below summaries the key elements of the P&L and Balance sheet



Q1-2010

Q1-2009

Growth
(EUR '000) (%)
Sales 6,353 6,925 -8.30%
EBITDA 1,387 1,581 -12.30%
EBITDA margin (%) 21.80% 22.80%
EBIT 787 1,067 -26.20%
EBIT margin (%) 12.40% 15.40%
Net income 784 967 -18.90%
Net margin (%) 12.30% 14.00%

Number of shares at March 31st. 17,554,354 17,554,354
Earnings per share EPS (EUR/share) 0.04 0.06

Equity 34,255 30,029 14.10%
Cash 9,128 1,479 517.20%
Interest-bearing liabilities 12,570 13,240 -5.10%
Net debt (cash) position 3,442 11,761 -70.70%
Gearing ratio 36.70% 44.10%
Total assets 65,718 55,264 18.90%


EBITDA: Earnings Before Interest, Taxes, Depreciation and Amortization
EBIT: Earnings Before Interest, Taxes

OUTLOOK

IBt Bebig stands today as an European leader in its segment: the treatment of early stage
cancer by brachytherapy. Its portfolio of products is now much better balanced than in the past and covers a wide range of different applications. The breakthrough achieved by the group, materialized in outstanding and historical results in 2009 and in this first quarter
2010, validates in retrospect the strategic move that was initiated during the summer of
2007.

At this stage, the Group confirms its outlook to show growing revenues and earnings for the full year 2010.

[R-BgO]

nachgelegt;

Eckert & Ziegler: Großauftrag für Prostatakrebsimplantate
02.06.2010 - Die Berliner Eckert & Ziegler Strahlen- und Medizintechnik AG hat über ihr belgisches Tochterunternehmen IBt BEBIG (International Brachytherapy S.A.) einen Großauftrag aus Frankreich für die Lieferung von Medizintechnik zur Prostatakrebsbehandlung erhalten.

In den nächsten drei Jahren wird der Strahlentherapiespezialist für mehrere Millionen Euro Miniaturimplantate zur Behandlung von Prostatakarzinomen in frühen Stadien an spezialisierte Krankenhäuser in Angers, Caen, Nizza, Straßburg und Rouen liefern. Der Auftrag umfasst auch die Belieferung des renommierten Institut Curie in Paris, in dem diese als Brachytherapie bezeichnete Form der Behandlung ursprünglich mitentwickelt wurde. Insgesamt werden voraussichtlich über 1.000 Patienten von den schwach-radioaktiven Implantaten profitieren.

Die auftraggebenden Kliniken sind Teil der Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), einem Zusammenschluss von 20 namhaften französischen Krebsforschungszentren, in der die staatlichen Aktivitäten Frankreichs im Bereich der Behandlung und Erforschung von Krebs koordiniert werden.

[GustavOemark]

Antwort auf Beitrag Nr.: 39.620.305 von R-BgO am 02.06.10 14:02:15

es ist doch sehr ruhig hier, während die Mutter neue Hochs erklimmt

[R-BgO]

A FIRST PATIENT TREATED FOR BRAIN CANCER USING IBT BEBIG SEEDS

Embargo until 5:40 pm (Belgian time) – July 6, 2010

Seneffe – Belgium, July 6, 2010, IBt Bebig (Reuters: IBTH.BR – Bloomberg: IBTB BB) has announced today that a first patient was treated for a brain tumor using IsoSeed®.

Recently, Dr. Matti Seppälä, used IsoSeed®, for a permanent brachytherapy seed implantation, to treat a patient with a chordoma tumor, at the Neurosurgery Department of the Helsinki University Central Hospital, Finland. For several years, this renowned institution treated patients that have parasellar/clival meningiomas or meningiomas in the elderly using brachytherapy.

The IsoSeed® from IBt Bebig is an Iodine-125 seed offering excellent visibility under high-contrast X-Ray or CT imaging and is today mostly used to treat early stage prostate cancer. IsoSeed® is registered for the treatment of prostate, brain and eye tumors.

Brachytherapy offers noticeable clinical and economical advantages over conventional radiotherapy techniques when treating brain cancers. The intracerebral implantation of Iodine-125 seeds through a stereotactic guiding system screwed at the patients skull for the biopsy, guarantees precise positioning of the radioactive seeds into brain tumor and results in a significantly prolonged survival, caused by high-dose irradiation of the brain tumor that is biologically comparable to high-dose fractionated radiotherapy – without fatal irradiation toxicity – with an improved healthy tissues sparing. Compared to conventional radiation therapy techniques, brachytherapy shows a real economical benefit for the healthcare system as it doesn't require large capital investments in treatment devices.

According to scientific publications, the technique of stereotactic implantation of I-125 (Iodine) seeds into intracranial meningiomas is relatively safe. Interstitial radiotherapy represents a potential tool in the control of medium-sized intracranial meningiomas, pilocytic astrocytomas, astrocytoma, oligodendrogliomas and oligoastrocytomas.

We are proud to see such a prestigious institution using our seeds. Like for the Breast Brachytherapy potential we were announcing recently, we look forward for the growing interest towards using IBt Bebig seeds for brain tumors. IBt Bebig is committed to help finding new ways to use brachytherapy as a treatment option , said Dr. Edgar Löffler, Managing Director of IBt Bebig

[R-BgO]

August 3, 2010

Seneffe – Belgium, August 3, 2010, IBt Bebig (Reuters: IBTH.BR – Bloomberg: IBTB BB) has today announced its consolidated results for the first-half year ending June 30, 2010.

The half-Year 2010 report including the management report and condensed consolidated interim financial statements for the 6 months ending June 30, 2010 can be downloaded at:
http://www.ibt-bebig.eu/en/investor_relations/financial_repo…

Sales for the first six months of 2010, representing the income generated by the sales of temporary brachytherapy equipments, i.e. HDR equipments using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called afterloaders ), ophthalmic plaques and permanent brachytherapy I-125 (Iodine-125) radiotherapeutic implants and therapy accessories, reached EUR 14.9 million, compared to EUR 16.5 million for the first semester of 2009, showing a decrease of 9.6%. In the first semester of 2010 about 10% of the sales figures are coming from the Russian project compared to 14% for the same period of 2009.

Earnings before interests and taxes (EBIT) reached EUR 2.6 million for the first semester of 2010 compared to EUR 3.2 million for the same period of 2009, showing a decrease of 18.6%.

Net profit reached EUR 1.7 million end of June 2010 compared to a net profit of EUR 2.9 million end of June 2009.

Total Equity of the group stood at EUR 35 million on June 30, 2010 versus EUR 33.4 million in December 31, 2009.

IBt Bebig also maintained a solid financial situation, with Cash amounting to EUR 6.3 million end of June 2010, versus EUR 9.6 million in December 2009. Net Debt stands at EUR 4.6 million, versus EUR 3.2 million in December 2009. The Equity to Assets ratio stood at 55% end of June 2010.

Outlook
Taking into account the current results and the anticipated course of business in the second half of the year, the management of IBt Bebig expects that revenue for the full year 2010 will be at the level of EUR 30 million. The EBIT margin will remain stable compared to 2009. With the world economy recovering, on the longer term the Group looks towards its future development and growth with clear optimism.

Shareholders Calendar

Trading Update 3Q-2010: Tuesday November 2, 2010
Annual Results 2010: Wednesday March 30, 2011
Trading Update 1Q-2011: Tuesday May 3, 2011
Annual General Meeting: Monday June 6, 2011 (10:30 am)
Half-Year Results 2011: Tuesday August 2, 2011
Trading Update 3Q-2011: Wednesday November 2, 2011

[GustavOemark]

diese Woche gab es im 2,50er Bereich schön Stücke
mit gefällt die Aktie recht gut auf dieser Basis (und natürlich auch darunter )
das EPS dürfte auch dieses Jahr über 0,20 Euro erreichen
die Expansion in die USA dürfte sich dann spät. nächstes Jahr in den Zahlen positiv bemerkbar machen

we will see
time will tell us

[GustavOemark]

Antwort auf Beitrag Nr.: 39.987.080 von GustavOemark am 15.08.10 16:11:33

und heute gab es sogar etwas unter 2,50

die "Mutter" steht weiter Stabil bei 24,40 Euro

[GustavOemark]

Eckert & Ziegler Strahlen- und Medizintechnik AG: Technologiesprung in der Prostatakrebsbehandlung. Erstmals Miniimplantate aus Kunststoff auf ESTRO Fachkongress vorgestellt

Eckert & Ziegler Strahlen- und Medizintechnik AG / Schlagwort(e):
Produkteinführung

21.09.2010 09:41
---------------------------------------------------------------------------

Berlin, 21.09.2010. Die IBt Bebig, ein belgisches Tochterunternehmen der
Eckert & Ziegler AG (ISIN DE5659700), hat auf dem europäischen
Strahlentherapiekongress in Barcelona erstmals Implantate zur Behandlung
von Prostatakrebs auf Kunststoffbasis vorgestellt, weltweit die ersten
ihrer Art. Sie sind in der Herstellung einfacher als traditionelle
Metallkapseln und erlauben eine noch präzisere Dosierung der verabreichten
Strahlung. Da sich die reiskorngroßen Miniimplantate wie Legosteine zu sehr
stabilen Ketten verknüpfen lassen, kann der Arzt damit eine individuell auf
den Patienten abgestimmte Dosierung wählen. Mit einsetzbaren Distanzhaltern
können die Abstände zwischen aktiven Elementen etwa an ungewöhnliche
Tumorformen angepasst und damit eine optimale Dosisverteilung im
betroffenen Organ erzielt werden. Auf breiter Basis sollen die
Miniimplantate mit dem Markennamen SmartSeed(R) etwa ab Mitte 2011 in
Europa eingeführt werden.

'Wir sind überzeugt, dass wir mit dem SmartSeed(R) unseren Marktanteil
innerhalb der permanenten Brachytherapie weiter ausbauen können', erklärte
Dr. Edgar Löffler, Mitglied des Vorstandes der Eckert & Ziegler AG und
verantwortlich für das Segment Therapie. 'Zudem eröffnen sich mit dem
patentgeschützten Produkt bisher verschlossene Märkte in Schwellenländern.
Kunststoffimplantate müssen erst auf der letzten Wertschöpfungsstufe
aktiviert, also strahlend gemacht werden, und lassen sich deshalb anders
als traditionelle Implantate profitabel auch als inaktives Produkt
exportieren. Es wird dadurch einfacher, weiter entfernte oder abgeschottete
Märkte zu erreichen.'

Prostatakrebs ist eine der häufigsten Krebserkrankung bei Männern, allein
in Europa gibt es jährlich rund 135.000 Neuerkrankungen. Als besonders
schonende Form der Behandlung für frühe Stadien des Prostatakarzinoms hat
sich die Brachytherapie bewährt, eine Spickung des befallenen Organs mit
winzigen radioaktiven Stiften. In den USA wird bereits jeder dritte
Prostatakrebspatient in dieser Form behandelt. Langzeitergebnisse zeigen,
dass Patienten mit lokalisiertem Prostatakarzinom damit ebenso effektiv und
im Durchschnitt wesentlich nebenwirkungsärmer als mit anderen Methoden
behandelt werden.

Die Eckert & Ziegler Gruppe ist ein Spezialist für isotopentechnische
Komponenten in der Strahlentherapie und Nuklearmedizin. Sie hat weltweit
540 Mitarbeiter und gehört in Europa zu den größten Anbietern von
Implantaten zur Prostatakrebsbehandlung.

Ihr Ansprechpartner bei Rückfragen:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin, Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail:
[e-mail], www.ezag.de

[GustavOemark]

Avatar #2762 von GustavOemark Benutzerinfo Nachricht an Benutzer Beiträge des Benutzers ausblenden 14.09.10 07:03:16 Beitrag Nr.: 40.144.909
Dieses Posting: versenden | melden Diskussion drucken

Folgende Antwort bezieht sich auf Beitrag Nr.: 40.144.765im neuen Fenster öffnen von Straßenkoeter am 14.09.10 00:31:10die Zahlen im ersten Halbjahr waren bei IBT schwächer - aber man erwartet immerhin bei das Rekordergebnis aus 2009 zu wiederholen (30 Mil. Euro Umsatz bei gleicher EBIT Marge) so jedenfalls die letzte Prognose
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66…

"Da liegt aktuell einiges im Argen bei Ibt."
wäre schön wenn Du dies spezifizieren könntes?

es hört sich doch eher danach an, dass die Seeds nun auch für andere Krebsarten Anwendung finden breites Grinsen
A FIRST PATIENT TREATED FOR BRAIN CANCER USING IBT BEBIG SEEDS
http://www.euroinvestor.co.uk/news/story.aspx?id=11162830

we will see - sollte bei IBT etwas im Argen liegen, dann hätte Eckert ziemlich teuer eingekauft (3,60 Euro und Kurs aktuell 2,20 Euro) und mittelfristig dürften Abschreibungen anstehen

ich denke jedoch eher, dass er in IBT berechtig sehr gutes Potential sah/sieht

die Aktie wird ihren Boden finden

time will tell us



aktueller Kurs: 2,60 Euro

2,20 bis 2,50 Euro waren Schnäppchenkurse

[GustavOemark]

die Erholung läuft
2,85 Euro

[R-BgO]

06.01.2011: IBt Bebig, ein Tochterunternehmen der Eckert & Ziegler AG und ein Hersteller von Krebsbestrahlungstechnik, hat sämtliche Anteile an der bayerischen SonoTech GmbH übernommen, einem Softwarehaus, das sich auf die Entwicklung von Software zur Bestrahlungsplanung spezialisiert hat.

Von dem in Neu-Ulm angesiedelten Unternehmen wurde unter anderem die Software für den Einsatz der Implantate entwickelt, die IBt Bebig zur Behandlung von Prostatakarzinomen anbietet. Darüber hinaus stellt die Firma Bestrahlungsplanungssoftware für die Tumorbestrahlungsgeräte der IBt Bebig her.

„Durch den Kauf und die Einbindung von SonoTech erhöhen wir unseren Anteil an der Wertschöpfungskette bei der Behandlung von Prostatakrebs und anderen Tumoren“, erklärte Dr. Edgar Löffler, Mitglied des Vorstandes der Eckert & Ziegler AG und verantwortlich für das Segment Therapie. „Zudem gewinnen wir die Möglichkeit, Software nach eigenen Vorstellungen weiterzuentwickeln. Wir sind sehr froh, die erfahrenden Softwareentwickler der SonoTech durch diesen Schritt an unsere Gruppe binden zu können, und sind sicher, damit unsere Wettbewerbsposition erheblich zu stärken.“

[Achtsamkeit]

Die folgende Meldung hat den Kurs nicht belastet.

+++

January 24, 2011
IBt Bebig files a complaint against Core Oncology

Seneffe - Belgium, January 24, 2011, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) has announced today that it has filed a complaint against Core Oncology, Inc. in the United States District Court in Seattle, to rescind an agreement with Core Oncology.

In November 2009 the parties agreed to form a strategic alliance. As part of that agreement, IBt Bebig acquired a takeover option for Core Oncology and granted a subordinated short term loan of US$ 2 million to Core Oncology. In the course of 2010, it turned out that the financial statements presented by Core Oncology at the time of both the execution of the agreement and the disbursement of the loan had to be revised and adjusted considerably. Following these adjustments, key financial data were significantly worse. In addition, Core Oncology did not repay the US$ 2 million note by its original maturity date, but rather claimed it had changed the maturity date and other terms without IBt Bebig's prior knowledge or approval, in transactions which IBt Bebig believes to be invalid.

Subsequently, IBt Bebig is alleging in its complaint that Core Oncology made misrepresentations about its financial condition intentionally or negligently. IBt Bebig is further alleging that Core Oncology acted in concert and conspired with third parties to tortiously interfere with Core Oncology's obligation to repay the preceding mentioned note. Accordingly, IBt Bebig is suing besides Core Oncology also three persons of its Board of Directors as well as two other parties related to the company's officers and Directors. Regarding internal accounting, as a precautionary measure, IBt Bebig decided to regroup the loan from non-current assets to doubtful debt.

"Discussions have been underway since a year between us and Core Oncology and it appears today that unfortunately the strategic alliance we wanted to build cannot be conclusive. Therefore we had to take this decision to file a complaint against Core Oncology. Nevertheless, the US market remains by far the largest in the World for permanent brachytherapy and we have a strong willingness to re-enter that market. As we are the leader in Europe, we already started looking for other opportunities to make a new trans-Atlantic alliance", commented Dr. Gunnar Mann, Managing Director of IBt Bebig.

Quelle:
http://www.ibt-bebig.eu/en/press/press_releases.html?user_hu…

[Achtsamkeit]

Eckert & Ziegler hat die Stücke von SMI übernommen und hält nun 78,22% der Stimmrechte an IBT.
Zusätzlich hält Eckert & Ziegler noch 50.000 warrants, die 0,22% entsprechen und bis Jahresende 2011 laufen.

++++++
1) 5.000 warrants held by Eckert & Ziegler expired on 31 December 2010. As a result thereof, Eckert & Ziegler currently owns only 50.000 warrants.
2) The transaction leading to this declaration is as follows: pursuant to an agreement of 22 December 2008, Eckert & Ziegler exercised on 21 March 2011 a call option on 5.000.000 beneficiary shares A of IBt held by SMI. The said agreement provides that the transfer of the beneficiary shares A from SMI to Eckert & Ziegler will take place upon payment of the price, which took placed on 25 March 2011.

Quelle:
http://www.ibt-bebig.eu/fileadmin/IR/Articles_of_Association…

[Achtsamkeit]

IBt Bebig Changes Its Name to Eckert & Ziegler BEBIG

June 29, 2011

Seneffe, Belgium, June 29, 2011, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB), a global leader in brachytherapy, announced today that it has changed its corporate name to Eckert & Ziegler BEBIG S.A.

As of July 1, 2011, the company will trade on the Euronext exchange under the new ticker symbol EZBG.

The name change was recommended and approved during the Extraordinary General Meeting held on June 6, 2011 in Seneffe.

The new name, Eckert & Ziegler BEBIG S.A., underlines the company's affiliation with the Eckert & Ziegler Group, one of the world's largest providers of isotope technology for medical, scientific, and industrial purposes. The Eckert & Ziegler Group has four business segments, Radiation Therapy, Radiopharmaceuticals, Isotope Products, and Environmental Services, all operated through its subsidiaries. With over 30 years' experience in the radiation therapy business, Eckert & Ziegler BEBIG S.A. will continue to drive the Group's leadership position.

"The vision behind the renaming has been to reinforce the fact that we are a part of a leading group with a well recognized name: Eckert & Ziegler. This supports our strategy of further worldwide expansion and our commitment to developing and providing medical devices and products to cure cancer and enhance the quality of life," said Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG S.A.

Cancer represents a major public health threat the world over. Radiation therapy is already prescribed for half of all cancer cases, and trends point to increased use. In this context, Eckert & Ziegler has set near-term objectives of globalizing the business, accelerating innovation, strengthening its portfolio, and ensuring supply.

Relationships with current business partners and customers will be managed through the same channels as before. The website domain name will change to www.bebig.eu. and all company email addresses will have the following format: [e-mail], as of July 1, 2011.

Quelle:
http://www.ibt-bebig.eu/en/press/press_releases.html?user_hu…

[R-BgO]

warum geht der Kurs so hoch?

Kurspflege oder jetzt doch squeeze-out?

[R-BgO]

Third Year in a Row with a Net Profit

March 30, 2012
Seneffe - Belgium, March 30, 2012, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its consolidated results for the year ending December 31, 2011.
A summary report including the milestones of the year 2011 and a selection of consolidated key figures for the 12 months ending December 31, 2011 can be downloaded at:
http://www.bebig.eu/investor_relations/financial_reports/int…
Sales for the year 2011 reached 30.4 million EUR, compared to 32.4 million EUR in 2010, showing a decrease of 6%. The main components were income generated by the sales of permanent brachytherapy I-125 radiotherapeutic implants as well as income from temporary brachytherapy equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders"). Beside the decrease of total sales, the stable recurring sales of goods and services increased by 6%.

Operating result reached 5.1 million EUR for the whole year 2011, compared to 6.0 million EUR in 2010, showing a decrease of 14%. Earnings before interest and taxes (EBIT) have reached 5 million EUR in 2011, versus 4.2 million EUR in 2010, showing an increase of 20.7%. It should be recalled that the EBIT result of 2010 has suffered a major impairment loss of 1.4 million EUR on a loan granted to Core Oncology Incorporation.

Cash amounted to 3.1 million EUR at the end of December 2011, versus 5.2 million EUR in December 2010. The equity to assets ratio stood at 66.7% end of December 2011.

Shareholders Calendar:
Trading Update 1Q-2012: Thursday, May 3, 2012
Annual General Meeting: Monday, June 11, 2012 (10:30 am)
Half-Year Results 2012: Tuesday, August 14, 2012
Trading Update 3Q-2012: Tuesday, November 6, 2012
The above results and trading updates will be published before market opens on the respective dates.

[R-BgO]

Antwort auf Beitrag Nr.: 42.529.919 von R-BgO am 29.12.11 14:53:31

tippe inzwischen auf Kurspflege, auch wenn mir nicht klar ist, wofür


company ist bei 5 Mio. EBIT noch mit 32 Mio. bewertet; scheint mir nicht teuer

außerdem könnte EZAG irgendwann auf die Idee kommen, sich die Notierung zu sparen

also Nachkauf?